Wei Ya Zhen Sheng Wu Ji Shu （ Su Zhou ） You Xian Gong Si

Primary objective: To demonstrate the efficacy of Plozasiran in reducing fasting serum TG levels. Secondary objectives: The proportion of subjects who achieved the target TG level reduction; To evaluate the efficacy of Plozasiran in the incidence of adjudicated abdominal clinical events. Safety objectives: To evaluate the safety and tolerability of Plozasiran; To evaluate the incidence of adjudicated major adverse cardiovascular events; To evaluate the immunogenicity of the trial drug) To evaluate the effect of Plozasiran on liver fat content. Exploratory objectives: To demonstrate the efficacy of Plozasiran in changes in lipid-related indicators; To evaluate the effects of Plozasiran on inflammation and exploratory serum biomarkers related to cardiovascular and metabolic diseases in the blood.